Company Description
Avalyn Pharma is a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs.
Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation.
Our current pipeline is focused on treating pulmonary fibrosis. Our most clinically advanced candidates, AP01 and AP02, are inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis, or PPF, and idiopathic pulmonary fibrosis, or IPF, respectively.
AP01 is currently being evaluated in MIST, a global Phase 2b clinical trial for the treatment of PPF.
AP02 is currently being evaluated in AURA, a global Phase 2 clinical trial for the treatment of IPF.
| Country | United States |
| Founded | 2011 |
| IPO Date | Apr 30, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Lyn Baranowski |
Contact Details
Address: 105 W First Street Boston, MA 02127 United States | |
| Phone | (206) 707-0340 |
| Website | avalynpharma.com |
Stock Details
| Ticker Symbol | AVLN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001540171 |
| Employer ID | 45-2463191 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lyn Baranowski | Chief Executive Officer and Director |
| Douglas Carlson | Chief Financial Officer and Chief Business Officer |
| Melissa Rhodes, Ph.D., D.A.B.T | Chief Operating Officer |
| Howard M. Lazarus, M.D., FCCP | Chief Medical Officer |
| Heather Turner | Director and Board Chair |
| Tiba Aynechi, Ph.D. | Director |
| Jill Carroll | Director |
| Jon Congleton | Director |
| David Friedman, M.D. | Director |
| Kate Haviland | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | 8-A12B | Registration of securities |
| Apr 23, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 8, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Mar 18, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Feb 6, 2026 | DRS | [Cover] Draft Registration Statement |
| Oct 10, 2023 | D | Notice of Exempt Offering of Securities |
| May 8, 2020 | D | Notice of Exempt Offering of Securities |
| May 24, 2017 | D/A | Filing |
| Mar 24, 2017 | D | Notice of Exempt Offering of Securities |
| Aug 12, 2015 | D/A | Filing |